Limits...
Alteration of melatonin secretion in patients with type 2 diabetes and proliferative diabetic retinopathy.

Hikichi T, Tateda N, Miura T - Clin Ophthalmol (2011)

Bottom Line: Nighttime melatonin levels were significantly lower in the diabetic group than in the nondiabetic group (P < 0.03) and lower in the PDR group than in the nondiabetic and NPDR groups (P < 0.01 and P < 0.03, respectively), but no significant difference was found between the nondiabetic and NPDR groups.The daytime melatonin level did not significantly differ between the nondiabetic and diabetic groups or between the nondiabetic, NPDR, and PDR groups.Alteration of melatonin secretion may accelerate further occurrence of complications in diabetic patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Ohtsuka Eye Hospital, Sapporo, Japan. taiichi-hikichi@hokkaido.med.or.jp

ABSTRACT

Background: The purpose of this study was to evaluate the dynamics of plasma melatonin secretion in patients with type 2 diabetes mellitus and diabetic retinopathy.

Methods: Plasma melatonin levels were measured by high-performance liquid chromatography in 56 patients. Patients were divided into a diabetic group (30 patients) and a nondiabetic group (26 patients). The diabetic group was divided further into a proliferative diabetic retinopathy (PDR) group (n = 14) and a nonproliferative diabetic retinopathy (NPDR) group (n = 16). Plasma melatonin levels obtained at midnight and 3 am were compared between the groups.

Results: Nighttime melatonin levels were significantly lower in the diabetic group than in the nondiabetic group (P < 0.03) and lower in the PDR group than in the nondiabetic and NPDR groups (P < 0.01 and P < 0.03, respectively), but no significant difference was found between the nondiabetic and NPDR groups. The daytime melatonin level did not significantly differ between the nondiabetic and diabetic groups or between the nondiabetic, NPDR, and PDR groups.

Conclusion: The nighttime melatonin level is altered in patients with diabetes and PDR but not in diabetic patients without PDR. Although patients with PDR may have various dysfunctions that affect melatonin secretion more severely, advanced dysfunction of retinal light perception may cause altered melatonin secretion. Alteration of melatonin secretion may accelerate further occurrence of complications in diabetic patients.

No MeSH data available.


Related in: MedlinePlus

Nighttime melatonin levels in each group. The nighttime melatonin level differed significantly between the nondiabetic (n = 26) and diabetic groups (n = 30, P < 0.03, Student’s t-test), and that level was significantly lower in the proliferative diabetic retinopathy group (n = 14) than in the nondiabetic and nonproliferative diabetic retinopathy groups (n = 16, P < 0.01 and P < 0.03, repeated-measures analysis of variance), but no significant difference was found between the nondiabetic and nonproliferative diabetic retinopathy groups.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3104794&req=5

f2-opth-5-655: Nighttime melatonin levels in each group. The nighttime melatonin level differed significantly between the nondiabetic (n = 26) and diabetic groups (n = 30, P < 0.03, Student’s t-test), and that level was significantly lower in the proliferative diabetic retinopathy group (n = 14) than in the nondiabetic and nonproliferative diabetic retinopathy groups (n = 16, P < 0.01 and P < 0.03, repeated-measures analysis of variance), but no significant difference was found between the nondiabetic and nonproliferative diabetic retinopathy groups.

Mentions: The nighttime and daytime melatonin levels were 35.5 ± 33.4 pg/mL and 2.8 ± 3.0 pg/mL in the nondiabetic group, 23.6 ± 30.1 and 1.0 ± 0.9 pg/mL in the diabetic group, 34.8 ± 37.4 and 1.33 ± 0.7 pg/mL in the NPDR group, and 10.9 ± 11.4 and 0.7 ± 0.9 pg/mL in the PDR group (Figures 2 and 3). The nighttime melatonin level was significantly lower in the diabetic group than in the nondiabetic group (P < 0.03, Student’s t-test) and in the PDR group than in the nondiabetic and NPDR groups (P < 0.01 and P < 0.03, repeated-measures analysis of variance), but no significant difference was found between the nondiabetic and NPDR groups. The daytime melatonin level did not significantly differ between the nondiabetic and diabetic groups, or between the nondiabetic, NPDR, and PDR groups.


Alteration of melatonin secretion in patients with type 2 diabetes and proliferative diabetic retinopathy.

Hikichi T, Tateda N, Miura T - Clin Ophthalmol (2011)

Nighttime melatonin levels in each group. The nighttime melatonin level differed significantly between the nondiabetic (n = 26) and diabetic groups (n = 30, P < 0.03, Student’s t-test), and that level was significantly lower in the proliferative diabetic retinopathy group (n = 14) than in the nondiabetic and nonproliferative diabetic retinopathy groups (n = 16, P < 0.01 and P < 0.03, repeated-measures analysis of variance), but no significant difference was found between the nondiabetic and nonproliferative diabetic retinopathy groups.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3104794&req=5

f2-opth-5-655: Nighttime melatonin levels in each group. The nighttime melatonin level differed significantly between the nondiabetic (n = 26) and diabetic groups (n = 30, P < 0.03, Student’s t-test), and that level was significantly lower in the proliferative diabetic retinopathy group (n = 14) than in the nondiabetic and nonproliferative diabetic retinopathy groups (n = 16, P < 0.01 and P < 0.03, repeated-measures analysis of variance), but no significant difference was found between the nondiabetic and nonproliferative diabetic retinopathy groups.
Mentions: The nighttime and daytime melatonin levels were 35.5 ± 33.4 pg/mL and 2.8 ± 3.0 pg/mL in the nondiabetic group, 23.6 ± 30.1 and 1.0 ± 0.9 pg/mL in the diabetic group, 34.8 ± 37.4 and 1.33 ± 0.7 pg/mL in the NPDR group, and 10.9 ± 11.4 and 0.7 ± 0.9 pg/mL in the PDR group (Figures 2 and 3). The nighttime melatonin level was significantly lower in the diabetic group than in the nondiabetic group (P < 0.03, Student’s t-test) and in the PDR group than in the nondiabetic and NPDR groups (P < 0.01 and P < 0.03, repeated-measures analysis of variance), but no significant difference was found between the nondiabetic and NPDR groups. The daytime melatonin level did not significantly differ between the nondiabetic and diabetic groups, or between the nondiabetic, NPDR, and PDR groups.

Bottom Line: Nighttime melatonin levels were significantly lower in the diabetic group than in the nondiabetic group (P < 0.03) and lower in the PDR group than in the nondiabetic and NPDR groups (P < 0.01 and P < 0.03, respectively), but no significant difference was found between the nondiabetic and NPDR groups.The daytime melatonin level did not significantly differ between the nondiabetic and diabetic groups or between the nondiabetic, NPDR, and PDR groups.Alteration of melatonin secretion may accelerate further occurrence of complications in diabetic patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Ohtsuka Eye Hospital, Sapporo, Japan. taiichi-hikichi@hokkaido.med.or.jp

ABSTRACT

Background: The purpose of this study was to evaluate the dynamics of plasma melatonin secretion in patients with type 2 diabetes mellitus and diabetic retinopathy.

Methods: Plasma melatonin levels were measured by high-performance liquid chromatography in 56 patients. Patients were divided into a diabetic group (30 patients) and a nondiabetic group (26 patients). The diabetic group was divided further into a proliferative diabetic retinopathy (PDR) group (n = 14) and a nonproliferative diabetic retinopathy (NPDR) group (n = 16). Plasma melatonin levels obtained at midnight and 3 am were compared between the groups.

Results: Nighttime melatonin levels were significantly lower in the diabetic group than in the nondiabetic group (P < 0.03) and lower in the PDR group than in the nondiabetic and NPDR groups (P < 0.01 and P < 0.03, respectively), but no significant difference was found between the nondiabetic and NPDR groups. The daytime melatonin level did not significantly differ between the nondiabetic and diabetic groups or between the nondiabetic, NPDR, and PDR groups.

Conclusion: The nighttime melatonin level is altered in patients with diabetes and PDR but not in diabetic patients without PDR. Although patients with PDR may have various dysfunctions that affect melatonin secretion more severely, advanced dysfunction of retinal light perception may cause altered melatonin secretion. Alteration of melatonin secretion may accelerate further occurrence of complications in diabetic patients.

No MeSH data available.


Related in: MedlinePlus